On November 21, a meeting focusing on the benefit mechanism of diabetic patients attracted attention, which was a satellite meeting at the 23rd National Academic Conference of Chinese Diabetes Society of Chinese Medical Association. The meeting was hosted by Hansoh Pharma and co-chaired by Professor Zhu Dalong of Nanjing Drum Tower Hospital Affiliated to Nanjing University and Professor Yang Wenying of China-Japan Friendship Hospital. A number of well-known experts in the field of diabetes presented the latest research progress of glucagon-like peptide 1 (GLP-1) receptor agonist and sodium-glucose co-transporter 2 (SGLT-2) inhibitor and discussed their benefit mechanism, which triggered a strong response.
Satellite Meeting at the 23rd National Academic Conference of Chinese Diabetes Society of Chinese Medical Association
Professor Yang Wenying pointed out that the cardiovascular benefit mechanism of GLP-1 drugs should be related to the double superposition effect of dosage exposure and time exposure of GLP-1 receptor agonist, which can bring multiple benefits such as cardiovascular protection to diabetic patients. Professor Tong Nanwei of West China Hospital of Sichuan University said that SGLT-2 inhibitor represented by canagliflozin has a clear mechanism of action and cardiorenal benefits, and is the first choice of treatment for patients with diabetes complicated with high-risk cardiovascular diseases and with chronic kidney diseases. Professor Zou Dajin of the First Affiliated Hospital of The Second Military Medical University proposed a 「221」 triple therapy scheme based on the pathophysiology of diabetes and new evidence. He pointed out that GLP-1 receptor agonist, metformin and SGLT-2 inhibitor are juxtaposed as first-line therapy options for patients with type 2 diabetes at different cardiovascular risk levels. The combination of the three can further improve the metabolism and cardiorenal protection of diabetic patients.
It is reported that the weekly GLP-1 preparation of Polyethylene Glycol Loxenatide, which has attracted much attention from experts attending the meeting, is the innovative drug Fulaimei independently developed by Hansoh Pharma over more than ten years. As the world's first pegylated long-acting hypoglycemic drug, Polyethylene Glycol Loxenatide monotherapy or combined therapy with metformin can comprehensively control blood sugar, significantly reduce HbA1c level and improve blood sugar compliance rate, has mild gastrointestinal adverse reactions, hypoglycemia incidence and antibody incidence, and provides multiple benefits such as improved pancreatic β cell function and weight loss; administration once a week greatly reduces the number of injections, resulting in simple injection operation and better patient compliance. The wide application of GLP-1 drugs represented by Polyethylene Glycol Loxenatide indicates that hypoglycemic therapy has entered a new era of 「cardiorenal benefits」 from 「intensive glucose control」. Also, according to public information, the first generic version of SGLT-2 inhibitor filed by Hansoh Pharma is expected to be approved in the near future.
The clinical efficacy of Polyethylene Glycol Loxenatide with multiple benefits is based on Hansoh's 「clinical needs centered」 R&D approach and the approach is integrated throughout all its R&D production lines. The diabetes production line is only one of the six major production lines of Hansoh Pharma. As a leader in China’s pharmaceutical innovation, Hansoh is in a strong position in the fields of central nervous system diseases and anti-tumor, and is also active in the fields of anti-infection, diabetes, gastrointestinal and cardiovascular therapy. We expect Hansoh Pharma to bring more benefits to patients with a wider range of products.
